8.7
Excellent
376 reviews
- Communication
- 8.8
- Timeliness
- 8.9
- Accuracy
- 7.6
- Staff
- 8.8
- Value
- 8.9
Mr. Doyle Yundt
5.4
- - Process Development
- - 14 weeks June - September 2024
- - Biotech Company
Reviewed:
Process development project faced delays, communication issues.
The process development project encountered multiple delays, and communication was inconsistent. We had to extend our project timeline due to the setbacks, and this impacted our overall production schedule. The team was capable but seemed overextended.
Tabitha Stoltenberg
8.6
- - Patient Engagement
- - 8 weeks August - September 2023
- - Clinical Research Organization
Reviewed:
Impressive patient engagement strategies, significant improvement in recruitment rates.
The patient engagement strategies implemented were impressive and led to a significant improvement in our recruitment rates. The team's experience in patient-centered approaches was evident and made a real difference.
Mr. Pablo Gleason
9.1
- - Pharmacovigilance Services
- - Ongoing
- - Pharmaceutical Company
Reviewed:
Highly effective pharmacovigilance services, ensured compliance.
The pharmacovigilance services ensured that our post-market surveillance was compliant and effective. The team was proactive in monitoring and reporting, providing us with peace of mind and ensuring patient safety.
Sue Sawayn
9.5
- - Gene Therapy Development
- - 12 weeks January - March 2023
- - Research Institution
Reviewed:
Innovative approach to gene therapy development, collaborative team.
The gene therapy project was managed exceptionally well, with innovative solutions provided at every stage. The team was highly collaborative and receptive to feedback, making it a truly joint effort. The results exceeded expectations.
Natasha Braun
6.5
- - Regulatory Submission
- - 8 weeks May - July 2024
- - Pharmaceutical Company
Reviewed:
Regulatory submission was incomplete, required additional work.
The initial regulatory submission provided was incomplete, requiring additional work to meet the necessary standards. This resulted in unexpected costs and delays. The team corrected the issues, but it should have been right the first time.
Terry McGlynn
9.1
- - Clinical Data Management
- - 6 weeks June - July 2023
- - CRO
Reviewed:
Timely and accurate data management, great collaboration.
The data management services were delivered on time and with great accuracy. Collaboration with the team was smooth, and they were always available to address any concerns or questions we had. We were very satisfied with the outcome.
Brittany Cronin
5.7
- - Project Management
- - 12 weeks March - May 2024
- - Biotech Company
Reviewed:
Poor communication and missed deadlines caused frustration.
Communication from the project management team was poor, with frequent missed deadlines. This caused significant frustration on our end, as we had to repeatedly chase them for updates. The project eventually got back on track, but the delays were problematic.
Mr. Leonard Hane
6.2
- - Clinical Protocol Design
- - 10 weeks January - March 2024
- - Pharmaceutical Company
Reviewed:
Inconsistent quality of deliverables, frequent revisions needed.
The protocol design process required multiple revisions due to inconsistencies in the deliverables. Although the team was responsive to feedback, the back-and-forth extended the timeline beyond what was originally agreed upon.
